Pfizer deal aims for greater drug specificity
This article was originally published in Scrip
Executive Summary
Pfizer is trying to make some of its drugs assets more tissue-specific. It has entered a preclinical collaboration with Cambridge, Massachusetts-based BIND Therapeutics to develop and commercialize highly selective, targeted and programmable drugs.